APAC IPO Calendar Sweep — Pan-Asia Listings Tracker

One pull. Every IPO across HKEX, TWSE, TSE, KRX, NSE/BSE, SGX and ASEAN — upcoming book-builds, this week's debuts, last quarter's vintage, post-IPO returns, sponsor league tables.

If you cover Asia as one bloc — long/short PMs, allocators, IPO traders, syndicate-desk strategists, the macro-Asia journalist — you have probably stitched this dataset together yourself, one exchange at a time, from HKEXnews + TWSE MOPS + JPX TDnet + KRX KIND + SEBI EDIFAR + SGX OPERA + IDX prospectus library + Bursa Malaysia + SET + HOSE + PSE EDGE. This actor does that stitching for you and bills per IPO row.

Who this is built for

If any of these is your day job, this actor was built for you:

• Pan-Asia long/short hedge fund PMs and allocators running multi-jurisdiction Asia books. You can't subscribe to Bloomberg, Refinitiv Eikon, Dealogic, S&P Global Market Intelligence, Asia Pacific Loan Market Association, Mergermarket Asia, The Edge Singapore Premium IPO, Korea Economic Daily IPO Database, Nikkei Asia IPO Tracker and Business Standard India IPO Database — but you need the merged feed.
• IPO traders running the Asia book at sell-side syndicate desks or proprietary trading shops. You need to know what's pricing tomorrow in Hong Kong, what's listing next week in Tokyo, what's mid-book-build in Mumbai, and what just broke -27% on its debut in Seoul. All in one query.
• Family offices and SWFs (GIC, Khazanah, Temasek, Mubadala, KIA peers) scanning cornerstone-investor allocations across pan-Asia deals. The cornerstone book is the single highest-signal datapoint in Asian primary markets — every pan-Asia mega-deal lists Hillhouse, Boyu, GIC, Norges Bank, Capital Group, Schroders, OrbiMed, Sequoia China, BlackRock and the China sovereign funds.
• Financial journalists covering Asia primary markets — Reuters, Bloomberg Asia, Nikkei Asia, South China Morning Post, Mint, Korea JoongAng Daily, Channel News Asia Business, DealStreetAsia and the Asia equity-research desks that feed them.
• Sector PMs building cross-Asia cohort studies. Semiconductors? Pull every Taiwan TPEx IPO + Korea KOSDAQ K-fabless + HK Chapter 18C + Japan TSE Growth-segment semi listing in one query. China-consumer? Pull Mixue, Chabaidao, Laopu Gold, Bawang Chaji, Chery Auto, Seres in one query. Biotech? Pull every HK Chapter 18A pre-revenue biotech + KOSDAQ Growth-tier K-biotech + India Lupin/Sun-Pharma-class IPO in one query.
• Allocators in Hillhouse / Boyu / Sequoia China / OrbiMed / Lake Bleu / Hony / Primavera / Bain Capital Asia / KKR Asia / Goldman Sachs Asia Special Situations-class funds scanning the comp set — who anchored what, at what valuation, at what return.

If you have ever budgeted USD 24,000+/year for a Bloomberg Terminal Asia primary-markets seat or USD 18,000+/year for a Dealogic Asia-Pacific subscription, you are the target buyer for this actor. Same fields, same coverage, same lifecycle granularity — billed per IPO row instead of per seat per year.

What you get per row

Every row is a single APAC IPO event. The schema is harmonised across all 11 markets so you can pivot, group-by and roll-up without per-country special-casing:

• country — Hong Kong, Taiwan, Japan, Korea, India, Singapore, Indonesia, Malaysia, Thailand, Vietnam, Philippines
• country_iso — ISO-2 country code (HK, TW, JP, KR, IN, SG, ID, MY, TH, VN, PH)
• exchange — HKEX, TWSE, TPEx, TSE, KOSPI, KOSDAQ, NSE/BSE, SGX, IDX, Bursa Malaysia, SET, HOSE, PSE
• company_name — issuer legal name in English / romanised
• stock_code — exchange-assigned ticker if listed (e.g. 2097.HK for Mixue Bingcheng, 285A.T for Kioxia, SWIGGY.NS for Swiggy, 5326.KL for 99 Speed Mart, AADI.JK for Adaro Andalan)
• sector — GICS-style 11-sector taxonomy (Technology / Healthcare / Financials / Consumer Discretionary / Consumer Staples / Industrials / Energy / Real Estate / Materials / Communication Services / Utilities)
• business_description — 1-3 line plain-English summary of what the company does
• listing_status — Upcoming / Pricing / Trading / Withdrawn / Postponed
• filing_date — date prospectus / Application Proof / DRHP / Lodgement was filed
• issue_date — pricing / book-close date (offer price finalised, allotment confirmed)
• listing_date — first-day-of-trading date in ISO-8601 (YYYY-MM-DD)
• offer_price_range — indicative price range from the red-herring prospectus
• offer_price — final offer price in local currency
• currency — ISO 4217 (HKD, TWD, JPY, KRW, INR, SGD, IDR, MYR, THB, VND, PHP)
• shares_offered — number of new shares in the offering
• proceeds_local_million — gross proceeds raised, local currency millions
• proceeds_usd_million — same, normalised to USD millions at recent FX
• valuation_local_million — post-money market cap at listing, local currency millions
• valuation_usd_million — same, USD millions
• sponsors — list of HKEX-sanctioned listing sponsors / SEBI book-running lead managers / SGX issue managers / JPX joint global coordinators (CICC, Goldman Sachs, Morgan Stanley, Nomura, Daiwa, Mirae Asset, Mizuho, Kotak Mahindra, Citi, JP Morgan, DBS, Maybank, Mandiri Sekuritas, etc.)
• cornerstone_investors — list of named cornerstone investors
• prospectus_url — link to the official prospectus filing on the relevant regulator portal (HKEXnews, MOPS Taiwan, JPX, KIND Korea, SEBI EDIFAR, MAS OPERA, IDX, Bursa Malaysia, SET, HSX, PSE EDGE)
• first_day_pop_pct — first-day close vs offer price (signed percentage)
• current_price — latest local-currency market price
• gain_loss_from_ipo_pct — total return from IPO price (signed percentage)
• source_actor — the underlying NexGenData country-specific IPO actor that contributed this row (e.g. nexgendata/hkex-ipo-calendar, nexgendata/sg-sgx-ipo-calendar)
• data_source — provenance tag

Concrete worked examples

Example 1 — "Every APAC IPO in the last 90 days, ranked by deal size."

{
  "country": "ALL",
  "status": "listed",
  "lookbackDays": 90,
  "limit": 100
}

Returns the recent vintage across every covered exchange — typically 30-80 IPOs depending on cycle. Sort the output by proceeds_usd_million descending in your downstream notebook to get the league table. This is the canonical end-of-quarter screen for Asia primary-market strategy notes.

Example 2 — "The forward pipeline of confirmed Asia mega-deals (USD 500M+)."

{
  "country": "ALL",
  "status": "approved",
  "lookaheadDays": 180,
  "minProceedsUsdMillion": 500,
  "limit": 50
}

Returns CATL HK A+H secondary ($4.6bn), Chery Auto HK ($1.2bn), Hengrui Pharma HK ($1.4bn), LG Electronics India NSE ($1.4bn), NTT DC REIT Singapore ($655M), Sakura Internet TSE secondary ($300M), Powerchip Taiwan secondary ($565M), Tokyo Metro TSE recently completed ($2.3bn historical), Kakao Pay Securities Korea (~$630M) and similar. Defines the H2 2026 Asia-IPO mega-deal pipeline.

Example 3 — "Every Indian IPO this quarter."

{
  "country": "IN",
  "status": "all",
  "lookbackDays": 90,
  "lookaheadDays": 90,
  "limit": 100
}

Drills into the world's most active IPO market by deal count. India NSE+BSE prices 200+ IPOs/year across mainboard + SME segments; this query returns the institutional-grade mainboard slice for the current quarter — Swiggy, Hyundai Motor India, NTPC Green, Vishal Mega Mart, plus forward names like LG Electronics India.

Example 4 — "ASEAN-only IPO pipeline for the next 6 months."

{
  "country": "ASEAN",
  "status": "approved",
  "lookaheadDays": 180,
  "limit": 50
}

Returns SGX (NTT DC REIT, Centurion Accommodation REIT, Info-Tech Systems), IDX Indonesia (forward), Bursa Malaysia, SET Thailand, HOSE Vietnam (Masan High-Tech Materials), PSE Philippines pipeline. Useful for the ASEAN-only allocator who doesn't trade North Asia.

Example 5 — "Every pre-revenue HK Chapter 18A biotech vs Korea KOSDAQ K-biotech in 2024-2026."

{
  "country": "ALL",
  "sector": "Healthcare",
  "status": "all",
  "lookbackDays": 730,
  "lookaheadDays": 180,
  "limit": 200
}

Returns the cross-Asia biotech IPO cohort — HK 18A vintage (Duality Bio, Hansoh Pharmaceutical Innovation) alongside KOSDAQ Growth-tier K-biotech (DXVX class) for cohort comparison.

Why pan-Asia coverage is uniquely hard (and uniquely valuable)

Asia primary-market data has historically been fragmented across 11+ regulators, 7+ alphabets/scripts, 9+ currencies, and several different lifecycle taxonomies. SEBI uses DRHP / RHP. HKEX uses Application Proof / PHIP. SGX uses Lodgement / Registration. TSE uses TDnet filings. KRX uses KIND disclosures. TWSE uses Public Information Observation. Bursa uses Mainboard / ACE / LEAP. Each has its own prospectus naming convention, its own sponsor/lead-manager nomenclature, its own quiet-period rules, its own cornerstone-investor disclosure regime.

Anyone who has built this dataset from scratch knows: the merged-feed problem is 80% of the work. This actor solves it. Every row is normalised to one schema, one currency-translation framework (we expose both local and USD), one lifecycle taxonomy (Upcoming → Pricing → Trading → optional Withdrawn / Postponed), and one sector taxonomy (GICS-style 11-sector).

The 11 markets we cover

• Hong Kong (HKEX) — Main Board + GEM. World #1 IPO venue by proceeds in 5 of the last 15 years (2009-2012, 2018). Active Chapters: 8A Weighted Voting Rights (Alibaba secondary, Xiaomi, Meituan), 18A pre-revenue biotech (InnoCare, BeiGene, Duality Bio class), 18C Specialist Technology Companies (Black Sesame, Plus AI, WeRide forward). 2024-2026 wave: A+H secondaries (Midea, S.F. Holding, CATL forward, Hengrui forward), China consumer brands (Mixue, Chabaidao, Laopu Gold).
• Taiwan (TWSE + TPEx) — Main board + Taipei Exchange (OTC) + TPEx Innovation Board. Home to the world's most strategic semiconductor IPO pipeline — TSMC supply chain (Phison, Realtek, Powerchip class).
• Japan (TSE) — Prime / Standard / Growth markets post-2022 restructure. Largest 2024-2026 deals: Tokyo Metro ($2.3bn), Kioxia ($770M), Rakuten Bank secondary, Sakura Internet GPU-cloud expansion.
• Korea (KRX — KOSPI + KOSDAQ) — KOSPI main-board (Samsung-class) + KOSDAQ growth (K-biotech, K-fabless, K-pop entertainment IPOs). Recent: HD Hyundai Marine Solution (97% first-day pop), LG Electronics secondary.
• India (NSE / BSE) — World's most active IPO market by deal count, ~200+ listings/year across mainboard + SME. Recent: Hyundai Motor India ($3.3bn — India's largest IPO ever), Swiggy ($1.4bn), NTPC Green ($1.2bn), Vishal Mega Mart, LG Electronics India forward.
• Singapore (SGX — Mainboard + Catalist) — Quality over quantity (5-30 IPOs/year). 2026 pipeline anchored by NTT DC REIT, Centurion Accommodation REIT, Info-Tech Systems.
• Indonesia (IDX) — Largest ASEAN market by GDP. 2024-2026 highlights: Adaro Andalan Indonesia ($350M+), MR DIY Indonesia ($270M+).
• Malaysia (Bursa Malaysia) — 99 Speed Mart Retail ($1bn+ — largest Malaysian IPO in a decade).
• Thailand (SET) — Big C, Berli Jucker class, SET-mai secondary universe.
• Vietnam (HOSE) — Frontier-Asia rising star. Masan High-Tech Materials forward.
• Philippines (PSE) — OceanaGold Philippines mining IPO.

Quick-start example

from apify_client import ApifyClient

client = ApifyClient("<YOUR_APIFY_TOKEN>")

run = client.actor("nexgendata/apac-ipo-calendar-sweep").call(run_input={
    "country": "ALL",
    "status": "all",
    "lookbackDays": 90,
    "lookaheadDays": 90,
    "limit": 100
})

for item in client.dataset(run["defaultDatasetId"]).iterate_items():
    print(item["country"], "|", item["company_name"], "|",
          item["listing_status"], "|", item.get("proceeds_usd_million"),
          "USD M", "|", item.get("first_day_pop_pct"), "% pop")

Sister NexGenData actors (cross-link hub)

This actor is the pan-Asia rollup tier of the NexGenData IPO product family. Pair it with the country-specific deep-dive actors when you need maximum lifecycle granularity for a single jurisdiction:

• nexgendata/hkex-ipo-calendar — HKEX Main Board + GEM with regulatory chapters (18A / 18C / 8A), sponsor list, cornerstone book, post-IPO return
• nexgendata/sg-sgx-ipo-calendar — Singapore Exchange Mainboard + Catalist
• nexgendata/ipo-tracker — US IPO tracker (NYSE / Nasdaq) with lockup expirations, S-1/F-1 filings, SEC EDGAR cross-references
• nexgendata/sec-form-13f-tracker-pro — US 13F institutional-holdings tracker (who bought what)
• nexgendata/sec-form-8k-material-events-scraper — US 8-K material-events monitoring
• nexgendata/earnings-calendar — global earnings calendar with EPS estimates

Pan-Asia equity screener fleet (pair with this actor)

If you trade the names after they list, pair the IPO calendar with the post-listing screeners:

• nexgendata/hkex-hang-seng-stock-screener — HKEX + Hang Seng Index
• nexgendata/eastmoney-china-stock-screener — Shanghai + Shenzhen A-shares
• nexgendata/twse-stock-screener — Taiwan Stock Exchange
• nexgendata/tse-japan-stock-screener — TSE Japan + Nikkei 225
• nexgendata/kospi-stock-screener — KOSPI + KOSDAQ (Korea)
• nexgendata/sgx-singapore-stock-screener — Singapore Exchange screener
• nexgendata/idx-indonesia-stock-screener — IDX Indonesia
• nexgendata/bursa-malaysia-stock-screener — Bursa Malaysia
• nexgendata/set-thailand-stock-screener — SET Thailand
• nexgendata/hose-vietnam-stock-screener — HOSE Vietnam
• nexgendata/pse-philippines-stock-screener — PSE Philippines

How this compares to the incumbents

	This actor	Bloomberg Asia IPO	Refinitiv Eikon APAC	Dealogic	The Edge Singapore Premium	Korea Economic Daily IPO DB
Cost	Per IPO row (sub-1% of seat)	USD 24,000+/seat/year	USD 22,000+/seat/year	USD 18,000+/year	SGD 600+/year (SG only)	KRW 1.2M+/year (KR only)
Pan-Asia coverage	11 markets in one query	Yes (one seat)	Yes (one seat)	Yes (one seat)	SG only	KR only
Forward calendar	Yes (announced + book-build + priced)	Yes	Yes	Yes (deal-flow focus)	SG only	KR only
Cornerstone investor lists	Yes	Yes	Yes	Partial	Yes (SG)	Yes (KR)
Regulatory chapter tags (HK 18A/18C/8A)	Yes	Partial	Partial	No	No	No
Per-IPO API access	Yes	Limited (terminal-licensed)	Limited (terminal-licensed)	Yes (enterprise tier)	No	No
FX-normalised USD proceeds	Yes (both local + USD)	Yes	Yes	Yes	No	No
Source actor traceability	Yes (per-country lineage)	No	No	No	No	No

For pan-Asia rollup work, the major incumbents (Bloomberg, Refinitiv, Dealogic) all require a full institutional seat per analyst. This actor charges per IPO row — the per-deal economics work out to fractions of a cent vs the per-seat economics of the incumbents.

Data sourcing

The curated database underlying this actor pulls from:

• HKEXnews + HKEX listing-committee hearing schedule
• TWSE MOPS Public Information Observation + Taipei Exchange (TPEx)
• JPX TDnet + TSE new-listing notices
• KRX KIND Korea Investor's Network for Disclosure
• SEBI EDIFAR + NSE/BSE listing prospectus archives
• MAS OPERA Singapore prospectus registry + SGX listing notices
• IDX Indonesia prospectus library
• Bursa Malaysia Mainboard listing notices + sponsor reports
• SET Thailand prospectus archive
• HSX HOSE Vietnam listing notices
• PSE EDGE Philippines disclosure portal
• Sponsor PHIPs (Post-Hearing Information Packs), DRHPs, prospectuses
• Bloomberg / Refinitiv / Nikkei Asia / Korea Economic Daily / The Edge Singapore / Mint / Business Standard / South China Morning Post / Channel News Asia Business IPO coverage
• Cornerstone-investor press releases

Records are hand-verified for deal size, sponsor list, cornerstone names and post-IPO return.

FAQ

Q: How fresh is the data?

The curated database covers 2024-01 through the forward 2026 calendar. Forward-pipeline rows (status Upcoming / Pricing) are refreshed on the announcement cadence of the underlying exchange filings — typically T+0 to T+3 from when the prospectus is lodged. Completed-IPO rows (status Trading) are post-debut and stable; current_price and gain_loss_from_ipo_pct snapshot at the last refresh of the curated database. For real-time post-listing pricing pair this actor with the country-specific stock screener actors listed above (HKEX, TWSE, TSE, KOSPI, SGX, IDX, Bursa, SET, HOSE, PSE all have dedicated screeners in the NexGenData fleet).

Q: How does the proof / approved / listed status taxonomy map to each exchange?

We normalise across the per-exchange lifecycles. proof covers early-stage filings (HKEX Application Proof, SEBI DRHP, SGX Lodgement, TSE TDnet pre-listing filings, KRX KIND preliminary disclosure). approved covers listing-committee-approved / book-building / RHP / PHIP / pricing-day deals. listed covers anything trading. all (default) returns the full lifecycle.

Q: Why is the proceeds figure sometimes in HKD millions and sometimes in IDR billions in the underlying data?

Each row preserves the local-currency figure in proceeds_local_million (always normalised to millions for consistency, even where local convention is otherwise — e.g. Indonesia would natively quote Rupiah trillions) and exposes an FX-normalised USD value in proceeds_usd_million. Sort/filter on the USD field for cross-Asia comparison; use the local-currency field for native-market analysis.

Q: Does this actor charge for empty result sets?

No. If your filters return no matches, we push a single no_match diagnostic row (which IS charged as one dataset item) with the active filters echoed back so you can debug, but the typical empty-result charge is one row, not the per-IPO premium tier. Tune lookbackDays / lookaheadDays if you see this.

Q: Can I get historical (pre-2024) data?

The curated database includes selected mega-deal history back to 2019 (Alibaba HK secondary, Saudi Aramco rumored HK dual listing) for reference. For systematic pre-2024 cohort studies, contact us via the NexGenData profile page — we can build a custom historical extract on the same schema.

Roadmap

• Real-time intra-day pricing-day signals (live offer-price-finalised feed at issue-date pricing close)
• Per-tranche allotment data (Hong Kong public-offer tranche oversubscription multiple, Indian retail/HNI/QIB allocation splits)
• Sponsor / book-runner league-table actor (sister actor apac-ipo-league-tables)
• Frontier-Asia coverage extension (Mongolia MSE, Kazakhstan AIX, Pakistan PSX)
• Greater-China A-share IPO calendar (Shanghai STAR Market + Shenzhen ChiNext + Beijing Stock Exchange — sister actor china-a-share-ipo-calendar planned)

Run NexGenData actors anywhere on the Apify platform

Sign up for Apify with our affiliate link: https://apify.com/?fpr=2ayu9b — supports continued development of the NexGenData fleet. You get the same Apify free tier ($5 platform credit / month); we get a small referral commission on any paid usage. Browse the full 280+ NexGenData actor catalog at https://apify.com/nexgendata?fpr=2ayu9b.